Alder BioPharmaceuticals to Present at Two Upcoming September Healthcare Conferences

BOTHELL, Wash., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast a business overview and update by members of the management team at each of the following upcoming healthcare conferences:

• 11th Annual Wells Fargo Securities Healthcare Conference at 11:05 a.m. ET on Wednesday, September 7, 2016 in Boston, MA 
• Morgan Stanley Global Healthcare Conference at 8:45 a.m. ET on Monday, September 12, 2016 in New York, NY

A live audio webcast of each event can be accessed on the Events & Presentations page of the Investors section of Alder’s website at http://investor.alderbio.com/index.cfm, or by following the links below in your web browser. An archived replay of the webcast will be available on Alder’s website for 30 days after the live event concludes.

• Wells Fargo link: https://cc.talkpoint.com/well001/090716a_ae/?entity=36_OH41YUV 
• Morgan Stanley link: https://cc.talkpoint.com/morg007/091216a_ae/?entity=4_REK0TUS

About Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, ALD403, is being evaluated for migraine prevention. ALD403 is a monoclonal antibody that inhibits calcitonin gene-related peptide, a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.

Media Contacts:
David Schull or Todd Davenport, Ph.D.
Russo Partners, LLC
(212) 845-4271
(212) 845-4235
[email protected]
[email protected]

Investor Relations Contact:
David Walsey
Alder BioPharmaceuticals
(425) 408-8032
[email protected]

Source: Alder BioPharmaceuticals, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• PetroTal Announces Corporate Updates
• Kneron Showcases the Latest EDGE GPT Solution at COMPUTEX 2024
• Ecora Resources PLC Announces Q1 2024 Trading Update